TrialJournal of gastrointestinal cancer2025

Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer.

Karin Potthoff et al.PubMed ↗Publisher ↗

No numbers read from the abstract.